Growth hormone (HGH)
Growth hormone (HGH) is a pulsatile peptide hormone secreted by the pituitary gland that regulates growth and metabolism primarily through insulin-like growth factor 1 (IGF-1). Its medical use is limited to carefully defined conditions. In performance- and image-enhancing use (PIED), evidence for its benefits remains limited, while the potential harms can be serious.
Updated 17 June 2026
Effects on body functions
The growth hormone (somatropin, somatotropin, or HGH) is the body’s peptide hormone, consisting of 191 amino acids and secreted from the anterior pituitary gland. The anterior pituitary produces the growth hormone in spurts and the concentrations vary considerably during the day. Most of the daily growth hormone is produced 1–2 hours after falling asleep. Physical stress (such as exercise), sleep (approximately 65% of growth hormone secretion occurs during sleep), low blood glucose levels/fasting, and amino acids stimulate growth hormone secretion. In contrast, high blood glucose levels (e.g., following carbohydrate intake), glucocorticoids (associated with chronic stress or corticosteroid treatment), and free fatty acids suppress its release. Growth hormone stimulates the liver to produce insulin-like growth factor 1 (IGF-1), which in turn inhibits growth hormone secretion through negative feedback mechanisms at the level of the hypothalamus and pituitary gland.
Growth hormone is secreted in a pulsatile manner, and its natural levels are influenced by numerous factors, including age, sex, body composition, nutrition, physical activity, and sleep quality. Growth hormone levels are highest during childhood and adolescence and gradually decline with age. [1, 2, 14, 20]
The growth hormone regulates growth among other things. The growth hormone affects the body through the insulin-like growth factors (IGF-1) produced mainly in the liver. The growth hormone also has effects that do not depend on IGF. Some of the effects are even contrary to those of IGF. One example of such is the effect on the blood sugar. The anabolic effect of the growth hormone is not entirely independent, however; rather, it requires IGF-1 in order to function effectively [3, 4].
The growth hormone has many kinds of effects on the metabolisms of carbohydrates and fat. The growth hormone is an anabolic (i.e. tissue-building) hormone that increases the transport of certain amino acids to cells and accelerates protein synthesis and affects the fat metabolism and the fluid balance of the body. The growth hormone enhances the muscle-growing effects of testosterone and anabolic steroids [5].
Production methods
All of the growth hormone preparations that are licensed in Finland are produced by recombinant DNA-technology.
Selling the growth hormone of human origin (i.e. made from the pituitary glands of deceased individuals) has been prohibited in Finland since 1988 due to the risk of the fatal Creutzfeldt-Jacob’s disease associated with it. The growth hormone of human origin has been sold on the black market, often camouflaged into a growth hormone manufactured by recombinant DNA-technology.
Dosage in medical use
The growth hormone dosage in medical use varies according to the disease being treated and its severity. When treating growth hormone deficiency in adults, the recommended initial dose is 0.15–0.3 milligrams (approximately 0.5–1 IU). In long-term treatment, the recommended dose is a maximum of 1–1.3 milligrams a day (3–4 IU/24 hrs). The average adult’s therapeutic dose of the growth hormone is 0.67 milligrams per day (2 IU/24 hrs).
Growth hormone is commonly administered as a once-daily subcutaneous injection, although newer formulations can be administered once weekly. [20]
Medical use
The growth hormone is a prescription drug that can be prescribed only by doctors who specialize in endocrinology, pediatric endocrinology or pediatric nephrology.
In the field of medicine, the growth hormone is mainly used for the treatment of growth disturbances caused by insufficient growth hormone secretion in children. Sometimes adults with remarkable growth hormone deficiency are treated with the growth hormone as well. However, this is rare. The most common causes are pituitary tumors and traumatic brain injury. Before starting the use of the growth hormone, the diagnosis must be carefully ascertained by exercise stress tests that measure the growth hormone secretion. [20] Doctors can be found guilty of malpractice if they prescribe the growth hormone to patients without seeing them or without careful diagnosis. Patients receiving the growth hormone must be monitored carefully, for example, by subjecting the patient to thyroid gland function tests and examinations for the possibility of glucose intolerance (i.e. sugar metabolism disorder). It is recommended that the growth hormone dosage is checked every six months.
PIED use
Under Finnish law, growth hormone is classified as a doping substance under Decree 705/2002 issued pursuant to Chapter 44, Section 16, Subsection 1 of the Criminal Code.
In non-medical performance- and image-enhancing (PIED) use, daily doses of growth hormone are often 1–2 mg, which is approximately three times higher than the body’s natural daily secretion. [15]
The growth hormone is used for its anabolic effects [6, 7]. It is thought to increase muscle mass and strength, to help the body adjust to heavy physical exertion, and to accelerate the healing of injuries. Growth hormone is rarely used on its own. It is often used in combination with anabolic steroids, insulin, and IGF-1. Among women, reported motivations for growth hormone use include improving sleep quality and joint mobility, enhancing skin appearance and overall well-being, and pursuing so-called anti-aging effects. [16]
In addition to the anabolic effect, the growth hormone has a fat-burning effect because it increases the breakdown of triglycerides and reduces the storage of fat [1]. Even professional cyclists have used the growth hormone due to its lipolytic effect to reduce body fat [8].
The growth hormone is a popular doping substance, but scientists have not been able to clinically prove its performance capacity-enhancing effect in full [3]. The main finding of a systematic review and meta-analysis published in 2017 was that the growth hormone increases fat-free mass to a reasonable extent and does reduce fat, but that it does not increase muscle strength or improve aerobic capacity in healthy young people. The added fat-free mass may mostly be caused by the accumulation of fluid. The greatest benefit of the growth hormone is probably obtained from the acceleration of recovery and the prevention of injuries due to the added collagen synthesis [9]. Moderate doses of the growth hormone alone were used in this study. Often, abused doses are higher and the growth hormone is used together with other anabolic substances. The potential effects are then different. However, the growth hormone functions very well in the case of a person suffering from a growth hormone deficiency [8, 14].
Growth hormone use has probably increased due to its cheapened price and the ease of ordering online. Marketing that promotes anti-aging benefits may also have contributed to the increasing popularity of growth hormone. The growth hormone can no longer be regarded as a doping substance of the elite athletes only. [10, 16]
Adverse effects
When the growth hormone is used in appropriate therapeutic doses, the most common adverse effects include joint and muscle pains and various types of swellings caused by fluid retention. The swellings may lead, among other things, to the increase of intracranial pressure or macular edema. Alternatively, they can lead to carpal tunnel syndrome.
Growth hormone reduces the effectiveness of insulin by increasing glucose production in the liver and decreasing glucose uptake by tissues. At the same time, it promotes the breakdown of adipose tissue, leading to elevated levels of free fatty acids in the blood and increased insulin resistance. As a result, acute overdose may initially cause a decrease in blood glucose levels due to the effects of IGF-1 and the body’s insulin response. However, blood glucose levels may subsequently rise as the diabetogenic, insulin-antagonistic effects of growth hormone begin to predominate [18]. In one case report, an individual administered an extremely large single dose of growth hormone and died as a result of severe poisoning [15].
Long-term use can cause hypertension, cardiomyopathies, diabetes and acromegaly (i.e. the excessive growth of the cartilages, the fingers and the chin) and roughening and thickening of the skin. The risk of certain cancers may grow (for instance, the risk of thyroid, breast and prostate cancers), but this is not certain [5, 6, 7, 11, 12, 13, 17].
Growth hormone use may contribute to the development of palumboism (steroid gut, HGH gut, abdominal enlargement). This condition is often associated with the combined use of growth hormone, insulin, and anabolic steroids. At high doses, growth hormone may promote the growth of internal organs. As a result of these combined effects, the abdominal region may become enlarged. [19]
Some known trade names (11/2025): Omnitrope, Genotropin, Norditropin, Saizen. [21]
Timo Seppälä
Medical Director
Finnish Center for Integrity in Sports FINCIS (previously the Finnish Antidoping Agency FINADA)
Updated by
Dopinglinkki
[1] Sane T. Aivolisäkkeen etulohko. 2010. In Dunkel L. Sane T, Välimäki M. Endokrinologia. Duodecim. (2nd edition)
[2] Velloso C. Regulation of muscle mass by growth hormone and IGF-1. Br J Pharmacol. 2008;154(3):557-568
[3] Anderson LJ, Tamayose JM, Garcia JM. Use of growth hormone, IGF-1 and insulin for anabolic purpose: Pharmacological basis, methods of detection and adverse effects. Mol Cell Endorcinol. 2017: S0303–7207(17)30337–4
[4] Dunkel L. 2010. Kasvuhormoni – kasvurustojärjestelmä. In Välimäki M, Sane T, Dunkel L. Endokrinologia. Duodecim Oppiportti
[5] Karila, Karjalainen, Mäntysaari, Viitasalo, Seppälä. Anabolic androgenic steroids produce dose-dependent increase in left ventricular mass in power athletes, and this effect is potentiated by concomitant use of growth hormone. International Journal of Sport Medicine. 2003; 24: 337–343
[6] Neely & Rosenfeld. Use and abuse of human growth hormone. Annual Review of Medicine. 1994; 45: 407–20
[7] Segura, Gutiérrez-Gallego, Ventura, Pascual, Bosch, Such-Sanmartín, Nikolovski, Pinyot & Pichini. Growth hormone in sport: beyond Beijing 2008. Therapeutic Drug Monitoring. 2009; 31(1): 3–13
[8] Holt R, Sönksen P. Growth hormone, IGF-1 and insulin and their abuse in sport. Brit J Pharmacol. 2008; 154:542–556
[9] Hermansen K, Bengtsen M, Kjær M, Vestergaard P, Jørgensen JOL. Impact of GH administration on athletic performance in healthy young adults: A systematic review and meta-analysis of placebo-controlled trials. Growth Horm IGF Res. 2017; 34:38–44
[10] Brennan B, Kanayama G, Hudson J, Pope Jr H. Human growth hormone abuse in male weightlifters. Am J Addict. 2011;20(1):9-13
[11] Karila, Koistinen, Seppälä, Koistinen & Seppälä. Growth hormone induced increase in serum IGFBP-3 level is reversed by anabolic steroids in substance abusing power athletes. Clinical Endocrinology. 1998; 49: 459–463
[12] Nicholls A, Holt R. Growth hormone and insulin-like growth factor-1. Front Horm Res. 2016; 47:101–14
[13] Pope H, Wood R, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an endocrine society scientific statement. Endocr Rev. 2014;35(3):341-375
[14] Siebert D, Rao A. The use and abuse of human growth hormone in sports. Sports Health. 2018;10(5):419-426
[15] Erfanifar A, Mahjani M, Gohari S, Hassanian-Moghaddam H. Fatal overdose from injection of human growth hormone; a case report and review of the literature. BMC Endoc Disord. 2022; 22:271
[16] Van Hout, M. C., & Hearne, E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subs Use Misuse, 2016;51(1):73–84
[17] Santi De, Baldelli G, Brandi G. Use of hormones in doping and cancer risk. Ann Ig. 2019;31(6):590-594
[18] Kim SH, Park MJ. Effects of growth hormone on glucose metabolism and insulin resistance in human. Ann Pediatr Endocrinol Metab. 2017; 22:145-152
[19] Suslin I, Efiemnko A, Castrellon R, Husain T. Abdominal hypertrophy syndrome: Characteristics and potential pathophysiology. Cureus. 2024;16(10): e72026
[20] Mäkimattila S, Markkanen H, Kastarinen H. Aikuisten kasvuhormonipuutos – diagnosoinnin ja hoidon päivitys. Lääketieteellinen Aikakauskirja Duodecim 2025;141(18):1461–9
[21] Duodecim Terveysportti. Lääketietokanta. Somatropiini. 11/2025
Like, share